Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Jan;27(1):60–64. doi: 10.1128/aac.27.1.60

Duration of effect of interferon aerosol prophylaxis of vesicular stomatitis virus infection in mice.

P R Wyde, C S Sun, S Z Wilson, V Knight
PMCID: PMC176205  PMID: 2984982

Abstract

Mice were exposed for 8 h to continuous small-particle aerosols containing natural mouse alpha interferon (estimated dosage 100 U per mouse) or one of two concentrations of hybrid recombinant alpha interferon A/D bgl (estimated dosages of 100 and 10,000 U per mouse, respectively). On days 1, 3, 5, 7, and 9 after exposure to these interferons, three mice from each group were inoculated intranasally with 100 PFU of vesicular stomatitis virus. Control mice were exposed to aerosols of saline or inoculated intraperitoneally with either natural mouse alpha interferon (350 U) or one of two doses of hybrid recombinant alpha interferon A/D bgl (350 or 35,000 U) and challenged similarly. Of mice injected intraperitoneally, only those given 35,000 U of hybrid recombinant alpha interferon A/D bgl 24 h before virus challenge were protected from pulmonary infection, compared with the saline-treated control mice. Of mice given 100 U of either interferon by small-particle aerosol, only those exposed 24 h before inoculation of vesicular stomatitis virus had reduced pulmonary titers of the virus. However, of mice given ca. 10,000 U of hybrid recombinant alpha interferon A/D bgl by small-particle aerosol, all groups except those exposed 9 days before virus inoculation had significantly reduced lung virus titers.

Full text

PDF
60

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blach-Olszewska Z., Mazur R., Skurska Z. The influence of route of administration of interferon on its therapeutic effect. Arch Immunol Ther Exp (Warsz) 1972;20(4):491–496. [PubMed] [Google Scholar]
  2. Dunnick J. K., Galasso G. J. Clinical trials with exogenous interferon: summary of a meeting. J Infect Dis. 1979 Jan;139(1):109–123. doi: 10.1093/infdis/139.1.109. [DOI] [PubMed] [Google Scholar]
  3. Greenberg S. B., Harmon M. W., Couch R. B., Johnson P. E., Wilson S. Z., Dacso C. C., Bloom K., Quarles J. Prophylactic effect of low doses of human leukocyte interferon against infection with rhinovirus. J Infect Dis. 1982 Apr;145(4):542–546. doi: 10.1093/infdis/145.4.542. [DOI] [PubMed] [Google Scholar]
  4. Greenberg S. B., Harmon M. W., Johnson P. E., Couch R. B. Antiviral activity of intranasally applied human leukocyte interferon. Antimicrob Agents Chemother. 1978 Oct;14(4):596–600. doi: 10.1128/aac.14.4.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Harmon M. W., Greenberg S. B., Johnson P. E., Couch R. B. Human nasal epithelial cell culture system: evaluation of response to human interferons. Infect Immun. 1977 May;16(2):480–485. doi: 10.1128/iai.16.2.480-485.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Harmon M. W., Greenberg S. B., Johnson P. E. Rapid onset of the interferon-induced antiviral state in human nasal epithelial and foreskin fibroblast cells. Proc Soc Exp Biol Med. 1980 Jun;164(2):146–152. doi: 10.3181/00379727-164-40838. [DOI] [PubMed] [Google Scholar]
  7. Heberling R. L., Kalter S. S. Persistence and spread of influenza virus (A2-Hong Kong) in normal and poly I.C. treated baboons (Papio cynocephalus). Proc Soc Exp Biol Med. 1970 Dec;135(3):717–723. doi: 10.3181/00379727-135-35128. [DOI] [PubMed] [Google Scholar]
  8. ISAACS A. INTERFERON. Adv Virus Res. 1963;10:1–38. [PubMed] [Google Scholar]
  9. Knight V., McClung H. W., Wilson S. Z., Waters B. K., Quarles J. M., Cameron R. W., Greggs S. E., Zerwas J. M., Couch R. B. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981 Oct 31;2(8253):945–949. doi: 10.1016/s0140-6736(81)91152-1. [DOI] [PubMed] [Google Scholar]
  10. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  11. Panusarn C., Stanley E. D., Dirda V., Rubenis M., Jackson G. G. Prevention of illness from rhinovirus infection by a topical interferon inducer. N Engl J Med. 1974 Jun 11;291(2):57–61. doi: 10.1056/NEJM197407112910201. [DOI] [PubMed] [Google Scholar]
  12. Pestka S. The human interferons--from protein purification and sequence to cloning and expression in bacteria: before, between, and beyond. Arch Biochem Biophys. 1983 Feb 15;221(1):1–37. doi: 10.1016/0003-9861(83)90118-2. [DOI] [PubMed] [Google Scholar]
  13. Rehberg E., Kelder B., Hoal E. G., Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem. 1982 Oct 10;257(19):11497–11502. [PubMed] [Google Scholar]
  14. Solov'ev V. D. The results of controlled observations on the prophylaxis of influenza with interferon. Bull World Health Organ. 1969;41(3):683–688. [PMC free article] [PubMed] [Google Scholar]
  15. Subrahmanyan T. P., Mims C. A. Fate of intravenously administered interferon and the distribution of interferon during virus infections in mice. Br J Exp Pathol. 1966 Apr;47(2):168–176. [PMC free article] [PubMed] [Google Scholar]
  16. Sun C. S., Wyde P. R., Wilson S. Z., Knight V. Efficacy of aerosolized recombinant interferons against vesicular stomatitis virus-induced lung infection in cotton rats. J Interferon Res. 1984 Fall;4(4):449–459. doi: 10.1089/jir.1984.4.449. [DOI] [PubMed] [Google Scholar]
  17. Wilson S. Z., Knight V., Moore R., Larson E. W. Amantadine small-particle aerosol: generation and delivery to man. Proc Soc Exp Biol Med. 1979 Jul;161(3):350–354. doi: 10.3181/00379727-161-40551. [DOI] [PubMed] [Google Scholar]
  18. Wyde P. R., Wilson S. Z., Kramer M. J., Sun C. S., Knight V. Pulmonary deposition and clearance of aerosolized interferon. Antimicrob Agents Chemother. 1984 Jun;25(6):729–734. doi: 10.1128/aac.25.6.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wyde P. R., Wilson S. Z., Sun C. S., Knight V. Interferon aerosol suppression of vesicular stomatitis virus replication in the lungs of infected mice. Antimicrob Agents Chemother. 1984 Oct;26(4):450–454. doi: 10.1128/aac.26.4.450. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES